Labarai

Wani binciken da aka yi a baya-bayan nan ya nuna tasirin CD7 CAR-T far wanda ya biyo baya na biyu na allogeneic hematopoietic stem cell transplantation (HSCT) a cikin marasa lafiya tare da sake dawowa T-cell m lymphoblastic cutar sankarar bargo (T-ALL) da lymphoblastic lymphoma (LBL), yana nuna gagarumin yiwuwar samun ƙarancin saura cuta (MRD) - rashin cikakkiyar gafara.

Wani bincike mai zurfi ya nuna nasarar da aka samu na CD19 CAR T-cell therapy a cikin kula da marasa lafiya tare da ciwon sankarar jini mai tsanani / refractory m lymphoblastic leukemia (ALL) bin allogeneic hematopoietic stem cell transplantation, yana ba da sabon bege a cikin ilimin halittar jini.

Bioocus yana kan gaba wajen haɓaka hanyoyin CAR-T masu zuwa. Buga na baya-bayan nan da Dokta Chunrong Tong da tawagarta a asibitin Lu Daopei suka buga ya nuna muhimman ci gaba da kalubale a cikin aikace-aikacen jiyya na CD19 CAR-T na ƙarni na biyu a cikin marasa lafiya na yara, yana nuna sadaukarwar Bioocus ga sabbin hanyoyin magance cutar kansa.

Wani bincike mai ban sha'awa yana nuna tasiri mai ban mamaki na CAR-T cell far a cikin maganin cutar sankarar bargo na B-cell Acute Lymphoblastic Leukemia (B-ALL). Binciken, wanda ya haɗa da haɗin gwiwa tare da BOOCUS da asibitin Lu Daopei, ya nuna ci gaba mai mahimmanci, kafa farfagandar a matsayin zaɓi mai mahimmanci.

Masu bincike daga Asibitin Lu Daopei da masu haɗin gwiwa na kasa da kasa sun bincika manyan hanyoyin kwantar da hankali na CAR-T, suna ba da bege ga marasa lafiya da ke da cututtukan ƙwayoyin cuta. Wannan binciken yana nuna ci gaba a cikin ƙira da aikace-aikace, yana nuna sakamako masu ban sha'awa da yuwuwar sabbin abubuwa na gaba.

Nazarin asibiti na baya-bayan nan ya nuna cewa sel CD19 na CAR-T na 4-1BB suna nuna ingantaccen ingancin antitumor idan aka kwatanta da sel CAR-T na tushen CD28 a cikin maganin sake dawowa ko refractory B cell m lymphoblastic leukemia (r/r B-ALL).

Wani bincike na baya-bayan nan a asibitin Lu Daopei ya nuna babban inganci da aminci na ƙananan ƙwayoyin CD19 CAR-T a cikin kula da marasa lafiya na lymphoblastic cutar sankarar bargo (B-ALL). Binciken, wanda ya haɗa da marasa lafiya 51, ya nuna cikakkiyar adadin gafara tare da ƙananan sakamako masu illa.

Asibitin Lu Daopei da Hebei Senlang Biotechnology sun ba da sanarwar sakamako masu ban sha'awa daga binciken da suka yi a baya-bayan nan kan aminci da ingancin maganin CAR-T don cutar sankarar ƙwayar cuta ta B cell. Wannan haɗin gwiwar yana nuna yuwuwar ƙirar sabbin ƙwayoyin CAR-T don haɓaka sakamakon haƙuri.

Wani sabon binciken da Dr. Zhi-tao Ying ya jagoranta daga Asibitin Ciwon daji na Jami'ar Peking ya nuna aminci da inganci na IM19 CAR-T tantanin halitta a cikin maganin sake dawowa da cututtukan cututtukan jini na B-cell. An buga a cikinJaridar Sinawa ta Sabbin Magunguna, Binciken ya ba da rahoton cewa 11 daga cikin marasa lafiya na 12 sun sami cikakkiyar gafara ba tare da mummunar tasiri ba, suna nuna yiwuwar IM19 a matsayin zaɓi na magani mai ban sha'awa ga marasa lafiya tare da iyakacin iyaka.

A cikin shekaru biyar da suka gabata, bincike kan sel Killer (NK) ya canza fahimtarmu game da rigakafi na asali, yana ba da sabbin hanyoyin da za a iya amfani da su don cutar kansa da cututtukan hoto.

Horarwar Shekara-shekara na 2024 don Kula da Jini na Clinical da Fasahar Canjawa a Garin Sanhe an yi nasarar gudanar da shi a Asibitin Yanda Ludaopei. Wannan taron yana da nufin haɓaka aikin kula da jini na asibiti da amincin jini ta hanyar cikakken zaman horo wanda sama da 100 kwararrun kiwon lafiya suka halarta daga cibiyoyin kiwon lafiya daban-daban.

Wani bincike na majagaba a Asibitin Jami’ar Erlangen ya yi nasarar yi wa wata yarinya ‘yar shekara 16 magani mai tsanani na lupus erythematosus (SLE) ta hanyar amfani da magungunan CAR-T. Wannan shine farkon amfani da wannan magani don lupus na yara, yana ba da sabon bege ga yara masu cututtukan autoimmune.